Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662319 · ClinicalTrials.gov registry record · Phase 3
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
A Phase 3 study of Hemophilia, sponsored by Sanofi.
- Active
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT05662319 is a Phase 3 study of Hemophilia that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 91 participants, below the 400-participant average among 9 other Hemophilia trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05662319, a Phase 3 study of Hemophilia, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. The total study duration will be up to approximately 50 months (200 weeks, 1 study month is equivalent to 4 weeks) and will include: * A screening period up to approximately 60 days, * A standard of care (SOC) period of approximately 6 study months (24 weeks), * A fitusiran treatment period of approximately 36 study months (144 weeks), * An antithrombin (AT) follow-up period of approximately 6 study months (24 weeks) but may be shorter or longer depending on individual participants AT recovery. The frequency for telephone visits will be approximately every 2 weeks. For site visits the frequency will be approximately every 8 weeks during the SOC period and approximately every 4 weeks during the fitusiran treatment period. If applicable and if allowed by local regulation, home and/or remote visits may be conducted during the study
Conditions Studied
Interventions
- DRUG Fitusiran
- DRUG Clotting factor concentrates (CFC) or bypassing agents (BPA)
- DRUG Antithrombin concentrate (ATIIIC)
Study Locations (20)
Other
- Investigational Site Number : 1560003 - Beijing
- Investigational Site Number : 1560001 - Guangzhou
- Investigational Site Number : 1560002 - Jinan
- Investigational Site Number : 2500003 - Le Kremlin-Bicêtre
- Investigational Site Number : 2500002 - Lille
- Investigational Site Number : 2500001 - Paris
- Investigational Site Number : 2760001 - Berlin
- Investigational Site Number : 2760002 - Hamburg
- Investigational Site Number : 3000001 - Athens
Ontario
- Investigational Site Number : 1240001 - Hamilton
- Investigational Site Number : 1240002 - Hamilton
- Investigational Site Number : 1240004 - Toronto
Texas
- Children's Medical Center Dallas- Site Number : 8400018 - Dallas
- Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400002 - Houston
California
- Center for Inherited Blood Disorders (CIBD) Site Number : 8400012 - Orange
Minnesota
- M Health Fairview University of Minnesota Medical Center - West Bank- Site Number : 8400016 - Minneapolis
New Jersey
- Hackensack University Site Number : 8400009 - Hackensack
New York
- Northwell Health Hemostasis and Thrombosis Center Site Number : 8400015 - New Hyde Park
Ohio
- University Hospitals of Cleveland Site Number : 8400001 - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2029-01-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05662319
The ClinicalTrials.gov registry entry for NCT05662319 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 400-participant average among 9 other Hemophilia trials with a reported enrollment target (77% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia appearing as the primary indexed condition, and to 3 interventions - of which Fitusiran is the first listed.
NCT05662319 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Ontario, Texas.
Frequently Asked Questions
What is clinical trial NCT05662319 about?
NCT05662319 is a clinical study titled "A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia". This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A ...
What is the current status of trial NCT05662319?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2023-02-01. Estimated completion is 2029-01-25.
What conditions does trial NCT05662319 study?
This clinical trial studies the following conditions: Hemophilia.
What interventions are being tested in trial NCT05662319?
The interventions under investigation include: Fitusiran (DRUG), Clotting factor concentrates (CFC) or bypassing agents (BPA) (DRUG), Antithrombin concentrate (ATIIIC) (DRUG).
Who is sponsoring clinical trial NCT05662319?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05662319 being conducted?
This trial has 20 study locations across California, Minnesota, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
RECRUITING · Phase 3
-
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
ACTIVE NOT RECRUITING · Phase 3
-
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
ACTIVE NOT RECRUITING · Phase 3
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
RECRUITING · Early Phase 1
-
The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.